Tools
ToolsPshezhetskiy, Dmitry, Alshaker, Heba and Stebbing, Justin (2014) Castrate-resistant prostate cancer: the future of antiandrogens. Trends in Urology & Men’s Health, 5 (1). ISSN 2044-3749
Preview |
PDF (Accepted manuscript)
- Accepted Version
Download (269kB) | Preview |
Abstract
Prostate cancer is the most common non-cutaneous cancer in North American and European men and the second leading cause of male cancer-related death [1]. The lifetime probability of developing prostate cancer in the UK is 14% [1] and in 2010 there were there were 40,975 new cases, accounting for 10,721 deaths [2]. Prostate cancer is associated with many risk factors, including age, family history, ethnicity, diet, and weight and although it is estimated that not more than 5% of all prostate cancer cases are hereditary, family history is appropriately considered a relevant risk factor. Many genetic changes have been associated with prostate cancer, including mutations in P53, P21, and P73 and tumour suppressor genes [3].
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | Pure Connector |
| Date Deposited: | 11 Jan 2017 00:06 |
| Last Modified: | 06 Jun 2024 14:57 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/61989 |
| DOI: | 10.1002/tre.371 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |